ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank

The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...